Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy

References

• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–137.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016;14:19–30.
   PubMed Web of Science ®Google Scholar
• Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131.
   PubMed Web of Science ®Google Scholar
• U.S. Social Security Administration. Period Life Table, 2013 [Internet] [cited 2017 May 21]. Available from: http://www.ssa.gov/OACT/STATS/table4c6.html.
   Google Scholar
• Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235–241.
   PubMed Web of Science ®Google Scholar
• Urushima H, Inomata-Kurashiki Y, Nishimura K, et al. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Male. 2015;18:72–76.
   PubMed Web of Science ®Google Scholar
• Haidar A, Yassin A, Saad F, et al. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male. 2007;10:189–196.
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174:827–834.
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–164.
   PubMed Web of Science ®Google Scholar
• Jhan JH, Yang YH, Chang YH, et al. Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study. Aging Male. 2017;20:33–38.
   PubMed Web of Science ®Google Scholar
• Joly F, Alibhai SM, Galica J, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176:2443–2447.
   PubMed Web of Science ®Google Scholar
• Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. 2000;36:1134–1141.
   PubMed Web of Science ®Google Scholar
• Schwandt A, Garcia JA. Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol. 2009;19:322–326.
   PubMed Web of Science ®Google Scholar
• Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516–1524.
   PubMed Web of Science ®Google Scholar
• Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456.
   PubMed Web of Science ®Google Scholar
• Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866–873.
   PubMed Web of Science ®Google Scholar
• Meng F, Zhu S, Zhao J, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016;16:180.
   PubMed Web of Science ®Google Scholar
• Owen PJ, Daly RM, Livingston PM, et al. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017;20:137–145.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Kim YB, Jung TY, et al. Radical prostatectomy in Korean men aged 75-years or older: safety and efficacy in comparison with patients aged 65–69 Years. J Korean Med Sci. 2016;31:957–962.
   PubMed Web of Science ®Google Scholar
• Mandel P, Kriegmair MC, Kamphake JK, et al. Tumor characteristics and oncologic outcome after radical prostatectomy in men 75 Years old or older. J Urol. 2016;196:89–94.
   PubMed Web of Science ®Google Scholar
• Xylinas E, Ploussard G, Paul A, et al. Laparoscopic radical prostatectomy in the elderly (>75 years old): oncological and functional results. Prog Urol. 2010;20:116–120.
   PubMed Web of Science ®Google Scholar
• Labanaris AP, Witt JH, Zugor V. Robotic-assisted radical prostatectomy in men ≥75 years of age. Surgical, oncological and functional outcomes. Anticancer Res. 2012;32:2085–2089.
   PubMed Web of Science ®Google Scholar
• Sivaraman A, Ordaz Jurado G, Cathelineau X, et al. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. World J Urol. 2016;34:1367–1372.
   PubMed Web of Science ®Google Scholar
• Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15:e404–e414.
   PubMed Web of Science ®Google Scholar
• Kawakami J, Cowan JE, Elkin EP, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106:1708–1714.
   PubMed Web of Science ®Google Scholar
• Potosky AL, Haque R, Cassidy-Bushrow AE, et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014;32:1324–1330.
   PubMed Web of Science ®Google Scholar
• Liu J, Shi L, Sartor O, et al. Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. Onco Targets Ther. 2013;6:725–732.
   PubMed Web of Science ®Google Scholar
• Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39–46.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010;28:3448–3456.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Benayoun S, et al. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244–1250.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–2425.
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–1500.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Jacobsen JB, Lash TL, et al. 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study. BMJ. 2012;344:e356.
   PubMed Web of Science ®Google Scholar
• Ingeman A, Andersen G, Hundborg HH, et al. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011;42:3214–3218.
   PubMed Web of Science ®Google Scholar
• Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184:918–923.
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol.. 2005;23:7897–7903.
   PubMed Web of Science ®Google Scholar